Clinical Trials Logo

Healthy Subjects clinical trials

View clinical trials related to Healthy Subjects.

Filter by:

NCT ID: NCT03100591 Completed - Healthy Subjects Clinical Trials

A Study to Evaluate ACT-132577 in Healthy Male Subjects

Start date: March 28, 2017
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to investigate the rate and routes (urine and feces) of elimination of ACT-132577, and the mass balance in urine and feces

NCT ID: NCT03099044 Completed - Healthy Subjects Clinical Trials

"Fermented Dairy Beverage on Inflammation/Immune Function in Stressful Exercise"

DAD
Start date: February 15, 2017
Phase: N/A
Study type: Interventional

The purpose of this pilot study is to determine the effects of a Single and Double Dose of Fermented Dairy Beverage on immune health and inflammatory status in healthy adults undergoing stressful exercise.

NCT ID: NCT03078088 Completed - Cystic Fibrosis Clinical Trials

Airway Alkalinization and Nasal Colonization

Start date: June 15, 2017
Phase: Phase 1
Study type: Interventional

The study will be a randomized, cross-over study of THAM followed by saline or saline followed by THAM in human non-CF and CF subjects to assess nasal colonization

NCT ID: NCT03072056 Completed - Healthy Subjects Clinical Trials

A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers

Start date: January 9, 2017
Phase: Phase 1
Study type: Interventional

- To evaluate the pharmacokinetic (PK) profile of MIN-101 and its metabolites in extensive (EM) and poor (PM) metabolizers - To evaluate the relationship between plasma levels of MIN-101 and changes in QT/QTcF intervals - To evaluate safety and tolerability of MIN-101.

NCT ID: NCT03049631 Completed - Healthy Subjects Clinical Trials

Red Raspberry Polyphenols on Gut Microbiome

RRB2
Start date: May 18, 2017
Phase: N/A
Study type: Interventional

The primary objective aims are to assess the effects of regular consumption of red raspberries (RRB) with and without fructooligosaccharide (FOS) on the composition of the gut microbiota after 4 week intake and in parallel characterize plasma and urine metabolite profiles examining qualitative and quantitative intervention associated changes.

NCT ID: NCT03038646 Completed - Healthy Subjects Clinical Trials

A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects

Start date: November 30, 2016
Phase: Phase 1
Study type: Interventional

- To evaluate the pharmacokinetic (PK) profiles of MIN-l0l following administration of modified release (MR) formulations of MIN-l0l in healthy male and female subjects - To select 1 MR formulation for use in fed state - To evaluate the effect of food on the bioavailability of MIN-l0l selected MR formulation

NCT ID: NCT03029806 Active, not recruiting - Healthy Subjects Clinical Trials

Lysine-specific Demethylase 1 and Salt-sensitivity in Humans

Start date: January 2, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the role dietary salt plays in epigenetic regulation of blood pressure, focusing on the salt-sensitive regulatory enzyme Lysine-specific demethylase 1.

NCT ID: NCT03017495 Completed - Healthy Subjects Clinical Trials

A Clinical Study to Investigate the Potential Interactions Between Food and ACT-541468 and Between ACT-541468 and Midazolam

Start date: January 1, 2017
Phase: Phase 1
Study type: Interventional

The main objectives of this phase 1 trial are to evaluate the effect of food on the pharmacokinetics (i.e. how long and how much a compound is present in the blood) of ACT-541468 and to evaluate whether ACT-541468 can affect the pharmacokinetics of midazolam, a CYP3A4 substrate.

NCT ID: NCT03014947 Completed - Healthy Subjects Clinical Trials

MSB11022 in Healthy Subjects

Start date: May 2014
Phase: Phase 1
Study type: Interventional

This is a phase I, randomized, double-blind, parallel-group trial to compare Investigation Medicinal Product (IMP) MSB11022, US- Reference Product (RP), and EU- Reference Medicinal Product (RMP) (Humira®) in healthy subjects.

NCT ID: NCT03008447 Completed - Healthy Subjects Clinical Trials

Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and Older

Start date: November 21, 2016
Phase: Phase 1
Study type: Interventional

E2006-A001-108 is a 4-period crossover study designed to demonstrate that the mean change from baseline in postural stability (worsening) when participants are awakened at approximately 4 hours postdose is significantly less after lemborexant than after zolpidem tartrate extended release following a single-dose administration at bedtime.